As previously mentioned, current results show elevated CAMKK1 in patients with T2DM, suggesting that CAMKK1 may be a biomarker capable of differentiating between individuals with obesity and patients with T2DM. Here, CAMKK1 is linked to obesity due to melanocortin 4 receptor deficiency.